Mealey's (July 30, 2019, 1:48 PM EDT) -- WASHINGTON, D.C. — A panel of the Federal Circuit U.S. Court of Appeals on July 29 affirmed dismissal by a federal judge in Delaware of patent infringement allegations stemming from an application to market a biosimilar version of Amgen Inc.’s “Neulasta” pegfilgrastim product, on the basis of prosecution history estoppel (Amgen Inc. v. Coherus Biosciences Inc., No. 18-1993, Fed. Cir., 2019 U.S. App. LEXIS 22394)....